D.A. Wallach Explains Why Biotech VC Is So Different
The business model of cutting-edge medicine.
D.A. Wallach
Photographer: Joe Scarnici/Getty Images Listen to Odd Lots on Apple Podcasts
Listen to Odd Lots on Spotify
Watch Odd Lots on YouTube
Subscribe to the newsletter
Most people think of venture capital as funding software startups or, these days, some new AI tool. But VC also plays a major role in developing new medicines and treatments. That’s the world of D.A. Wallach — though he didn’t start there. Before becoming a biotech investor, Wallach was the lead singer of the indie rock band Chester French. So how did he make the leap from music to venture capital? How does he spot promising biotech opportunities? What does it actually take to bring a new drug to market? And how does biotech investing differ from traditional VC? We talk to the co-founder of Time BioVentures about all of this — plus we get his thoughts on AI’s impact on music and a special performance.